Scientific depth.
Strategic perspective.

For more than two decades, Mukhtar has worked across fundamental biology and the decisions that turn research into development programs. His central question is practical: which scientific opportunities deserve a company’s capital, talent, and time?

His approach begins with the biology: what has been observed, what can reasonably be inferred, and what remains an assumption. He brings that discipline to clinical development, portfolio prioritization, and company formation, assessing whether a program is scientifically credible, clinically plausible, and commercially coherent.

From discovery to development

As Director of Project and Portfolio Strategy at Greenstone Biosciences, Mukhtar leads translational strategy and portfolio execution at a venture-backed biotech. His responsibilities span preclinical development, international clinical studies, external partnerships, and the operating systems needed to support funded programs.

• Development execution. Led the company’s lead asset through IND-enabling studies and preparations for first-in-human Phase I development; directed DMPK, toxicology, and regulatory work across two IND-enabling programs.
• Clinical evidence. Manages a portfolio of five international Phase Ib/IIa studies in heart failure, with responsibilities spanning enrollment, study execution, and primary readout.
• Financing and company formation. Contributed to Series A fundraising and helped shape the spinout strategy for two clinical-stage companies.
• Competitive funding. Secured $4.1 million in NIH and CIRM funding, including $2.75 million from NIH and $1.35 million from CIRM, to advance iPSC-based platforms and the Clinical Trial in a Dish program.
• Partnerships and operating discipline. Negotiated a global CRO partnership, prepared systems for NIH and SBIR audits, and designed a framework for cross-border handling of genetic data. He is a named inventor on US patent application 18/955,706.

Earlier, as Senior Scientist and Strategic Development Lead, he led discovery and preclinical studies, developed the market-entry strategy for Greenstone’s biobank, and prepared clinical trial infrastructure.

Advisory and venture work

Beyond his operating role, Mukhtar serves as Strategic Advisor to Accanito Therapeutics and Venture Advisor to Magnet Ventures. At Accanito, he advises the CEO on clinical development, including the transition from investigator-initiated to company-sponsored trials, indication prioritization for a pan-cancer asset, and development planning ahead of financing.

His advisory interests center on the decisions facing founders, investors, and boards: reading the biology, testing development assumptions, allocating capital, and determining whether a scientific opportunity can support an independent company.

Scientific foundation

Mukhtar’s doctoral and postdoctoral work spans GPCR and G protein signaling, epithelial polarity, vesicle trafficking, proteomics, and single-molecule imaging. At Vanderbilt, he developed imaging and CRISPR-based approaches to study protein dynamics, led research programs, and mentored doctoral trainees. His publications include work in Nature Communications, Current Biology, and the Journal of Experimental Medicine.

Executive education through Wharton and London Business School complements his scientific training with business analytics, strategy, and leadership.

Writing and public ideas

Mukhtar writes about drug development, AI, innovation systems, capital allocation, and leadership under uncertainty. His essay The Dual Mandate: Profit and Public Good in Pharmaceutical Corporations examines the relationship between therapeutic value and commercial responsibility. His work also appears in The Daily Star, Medium, and Substack.

Before Strategy, a book in development, examines the judgment, questions, and choices that precede a strategic plan.